For Healthcare Professionals

Eva W. is an actual patient living with seizure clusters.
Eva's mother is an employee of UCB, Inc.

NAYZILAM: A ready-to-use treatment for seizure clusters

NAYZILAM® (midazolam) nasal spray, CIV is a rescue medication indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.

On this page, there is a variety of information about NAYZILAM that you may find useful.

  • You can review details about dosing, patient savings, and Prescribing Information.
  • You can also request a training kit and register to receive other NAYZILAM product information.
NAYZILAM nasal spray device

Dosing and how to administer

NAYZILAM can be administered by a non-healthcare professional and no priming is necessary. This rescue treatment may be administered to a patient during or after a seizure within a cluster. NAYZILAM requires no active inhalation and can be used whenever a seizure cluster occurs — at home, school, or work.

Using Nayzilam
NAYZILAM savings card

SAVINGS AND ACCESS FOR PATIENTS

Discover how you can help make NAYZILAM more affordable for patients with the NAYZILAM Patient Savings Card.

There are three ways that your eligible commercial patients can check their eligibility and sign up for savings:

  • Register on the NAYZILAM Savings page
  • Text “JOINNAYZ” to 50566 to sign up for NAYZILAM Patient Savings Card and SMS product reminder alerts. Message and data rates may apply. Four (4) messages per month.
  • Call 1-888-786-5879

Financial assistance may be available for NAYZILAM patients. The NAYZILAM Patient Assistance Program may be able to help if your patients do not have health insurance or otherwise cannot afford NAYZILAM.

To learn more about the NAYZILAM Patient Assistance Program or to find out if your patients might be eligible for assistance, please contact ucbCARES® at 833-948-2394 or ucbCARES@ucb.com.

Help Patients Access NAYZILAM
NAYZILAM Prescribing Information

Prescribing NAYZILAM

Here are some considerations for prescribers prior to initiation of treatment.

Prescribing Information
NAYZILAM training kit

Request a NAYZILAM training kit

The NAYZILAM training kit includes information to help patients and their caregivers practice how to give the nasal spray, so everyone can feel reassured that they know what to do during a seizure cluster. See what's inside the training kit.

The training kit includes one training device, which is meant to model the real NAYZILAM product in look and feel, but without any actual medicine. Holding the device and pressing the plunger will simulate what it feels like to use an actual device. This training device can be reset and practiced with repeatedly, while the prescribed device with medication can only be used one time.

REQUEST KIT

Already have a training kit and would like to order more? Learn how to request additional training kits here.

Receive product information

You can register to receive relevant information or any updates about NAYZILAM by filling out the form below. When registering, you may also request a NAYZILAM training kit by mail.

ARE YOU A SCHOOL NURSE?

CLICK FOR MORE INFORMATION

 If you are interested in additional resources or training kits, please contact us by email.

Send request

CONTACT

ucbCARES helps patients start and stay on treatment as appropriate. Contact ucbCARES for support regarding UCB neurology prescriptions.

Call 833-948-2394
Monday through Friday,
9:00 AM to 6:00 PM ET

Visit
ucbCARESneuro.com

Email
ucbCARES@ucb.com

Submit e-Rx for NAYZILAM to
NCPDP #5910206 (Sonexus™ Health Pharmacy) to fax Rx to 855-338-1386

NCPDP = National Council for Prescription Drug Programs.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

NAYZILAM is contraindicated in patients with acute narrow-angle glaucoma.

RISKS FROM CONCOMITANT USE WITH OPIOIDS

Concomitant use of benzodiazepines, including NAYZILAM, and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.

ABUSE, MISUSE, AND ADDICTION

The use of benzodiazepines, including NAYZILAM, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing NAYZILAM and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction.

DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF NAYZILAM MORE FREQUENTLY THAN RECOMMENDED

The continued use of benzodiazepines may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Although NAYZILAM is indicated only for intermittent use, if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of NAYZILAM may precipitate acute withdrawal reactions, which can be life-threatening. For patients using NAYZILAM more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue NAYZILAM.

RISKS OF CARDIORESPIRATORY ADVERSE REACTIONS

Serious cardiorespiratory adverse reactions have occurred after administration of midazolam. Warn patients and caregivers about the risks of respiratory depression, cardiac and respiratory arrest.

Respiratory depression was observed with the administration of NAYZILAM during clinical trials. Cardiac or respiratory arrest caused by NAYZILAM was not reported during clinical trials.

CENTRAL NERVOUS SYSTEM DEPRESSION FROM CONCOMITANT USE WITH OTHER CENTRAL NERVOUS SYSTEM DEPRESSANTS, OR MODERATE OR STRONG CYP3A4 INHIBITORS

Drug products containing midazolam, including NAYZILAM, have a central nervous system (CNS) depressant effect.

Risks from Concomitant Use with Other CNS Depressants

NAYZILAM may cause an increased CNS-depressant effect when used with alcohol or other CNS depressants (e.g., opioids). Warn patients and caregivers that the use of NAYZILAM in combination with alcohol or other CNS depressant drugs may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.

Risks from Concomitant Use with Moderate or Strong CYP3A4 Inhibitors

Concomitant use of NAYZILAM with moderate or strong CYP3A4 enzyme inhibitors may result in prolonged sedation because of a decrease in plasma clearance of midazolam. Caution patients against engaging in hazardous occupations requiring mental alertness, such as operating machinery, driving a motor vehicle or riding a bicycle until they have completely returned to their level of baseline functioning.

SUICIDAL BEHAVIOR AND IDEATION

Antiepileptic drugs (AEDs), including NAYZILAM, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Monitor patients treated with NAYZILAM for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Advise patients and caregivers to be alert for these behavioral changes and to immediately report them to the healthcare provider.

IMPAIRED COGNITIVE FUNCTION

Midazolam, including NAYZILAM, is associated with a high incidence of partial or complete impairment of recall for several hours following an administered dose. Counsel patients on when they can engage in activities requiring complete mental alertness, operate hazardous machinery, or drive a motor vehicle after taking NAYZILAM.

GLAUCOMA

Benzodiazepines, including NAYZILAM, can increase intraocular pressure in patients with glaucoma. NAYZILAM may be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. NAYZILAM is contraindicated in patients with narrow-angle glaucoma.

NEONATAL SEDATION AND WITHDRAWAL SYNDROME

Use of NAYZILAM late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in the neonate. Monitor neonates exposed to NAYZILAM during pregnancy or labor for signs of sedation and monitor neonates exposed to NAYZILAM during pregnancy for signs of withdrawal; manage these neonates accordingly.

ADVERSE REACTIONS

In the randomized, double-blind, placebo-controlled trial, the most common adverse reactions (5% in any NAYZILAM treatment group) were somnolence, headache, nasal discomfort, throat irritation, and rhinorrhea.

NAYZILAM is a Schedule IV controlled substance.

Please see full Prescribing Information.

See More

IMPORTANT SAFETY INFORMATION

NAYZILAM is contraindicated in patients with acute narrow-angle glaucoma. Concomitant use of benzodiazepines, including NAYZILAM, and opioids may result in profound sedation, respiratory depression, coma, and death. The use of benzodiazepines, including NAYZILAM, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. The continued use of benzodiazepines may lead to clinically significant physical dependence. Although NAYZILAM is indicated only for intermittent use, if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of NAYZILAM may precipitate acute withdrawal reactions, which can be life-threatening. NAYZILAM may cause increased CNS-depressant effect when used with alcohol or other CNS depressants. Concomitant use with moderate or strong CYP3A4 inhibitors may result in prolonged sedation due to a decrease in plasma clearance of midazolam. Antiepileptic drugs, including NAYZILAM, increase the risk of suicidal ideation and behavior. Midazolam is associated with a high incidence of partial or complete impairment of recall for the next several hours.

SELECT IMPORTANT SAFETY INFORMATION

Concomitant use of benzodiazepines, including NAYZILAM, and opioids may result in profound sedation, respiratory depression, coma, and death. The use of benzodiazepines, including NAYZILAM, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. The continued use of benzodiazepines may lead to clinically significant physical dependence.

(Select arrow above for complete Important Safety Information)